TJ107

DRUG2 trials

Sponsors

TJ Biopharma Co., Ltd.

Conditions

Advanced Solid TumordNewly Diagnosed Glioblastoma

Phase 1

Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TJ107 in Chinese Patients With Advanced Solid Tumors

CompletedNCT04001075

TJ Biopharma Co., Ltd.Advanced Solid Tumord

Start: 2019-02-25End: 2021-09-23Updated: 2024-04-15

Phase 2

A Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients With Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT)

Active, not recruitingNCT04600817

TJ Biopharma Co., Ltd.Newly Diagnosed Glioblastoma

Start: 2020-12-31End: 2024-12-31Target: 160Updated: 2024-04-15

Related Papers

Efficacy of Shenglin decoction in preventing acute severe lymphocytopenia in patients with non-small cell lung cancer undergoing concurrent chemoradiotherapy: a study protocol for a randomized controlled trial

Frontiers in Oncology2024-05-08